PDX Volumetric Analyzer

The PDX Volumetric Analyzer (PVA) in an R Shiny application developed by members of PDXNet to improve the accessibility of the proposed metrics for assessment of antitumor efficacy presented in Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations (Meric-Bernstam et al. 2024). PVA allows users to validate and then import custom tumor volume (TV) data sets. From these data, PVA computes basic statistics, and generates plots using the best practices provided in Meric-Bernstam et al. (2024). These assessment cover a wide range of tumor volume response metrics (e.g., tumor growth inhibition, RECIST, event free survival, analysis of variance).

Access the PVA Shiny application here: https://pdxnet.shinyapps.io/PDX-Volumetric-Analyzer/

See the associated publication for more details: Funda Meric-Bernstam, Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis, Kurt W. Evans, Dali Li, Lawrence Rubinstein, Alana Welm, Dennis A. Dean, Anuj Srivastava, Jeffrey W. Grover, Min J. Ha, Huiqin Chen, Xuelin Huang, Kaushik Varadarajan, Jing Wang, Jack A. Roth, Bryan Welm, Ramaswamy Govinden, Li Ding, Salma Kaochar, Nicholas Mitsiades, Luis Carvajal-Carmona, Meenhard Herylyn, Michael A. Davies, Geoffrey I. Shapiro, Ryan Fields, Jose G. Trevino, Joshua C. Harrell, NCI PDXNet Consortium, James H. Doroshow, Jeffrey H. Chuang, Jeffrey A. Moscow; Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther 1 July 2024; 23 (7): 924–938. https://doi.org/10.1158/1535-7163.MCT-23-0471

PVA Landing Page

Funding is provided by the NIH to the PDXNet Data Commons and Coordination Center (NCI U24-CA224067), and to the PDX Development and Trial Centers (NCI U54-CA224076, NCI U54-CA224083, NCI U54-CA224070, NCI U54-CA283759, NCI U54-CA283766, and U54-CA283762)